Bupropion XL

ApprovedSmall molecule

GSK

Bupropion XL is one of 211 small molecule programs targeting Dysthymic Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

210

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dysthymic DisorderActive, not recruiting

Cocaine DependenceActive, not recruiting

Breast CarcinomaCompleted

MemoryActive, not recruiting

Major Depressive DisorderActive, not recruiting

Bipolar DisorderActive, not recruiting

Dysthymic DisorderApproved

Active, not recruiting

Cocaine DependencePhase 2/Phase 3

Active, not recruiting

Breast CarcinomaPhase 2

Completed

MemoryPhase 3

Active, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Bipolar DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Elavil

AstraZeneca

Phase 3

2 3

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 4

Bupropion XL

GSK

Approved

1 5

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 6

Risperdal

WWim Janssens

Phase 3

2 7

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 8

Quetiapine XR

AstraZeneca

Phase 3

4 9

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 10

Comparator: Pbo

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

MPA

NCT07269873

Clinical

Trials by Indication[1]

ESS1 trial

Connectivity Affecting the Antidepressant REsponse Study

Completed·VVanderbilt University Medical Center·Phase 4·NCT02332291·95 enrolled

Major Depressive Disorder1 trial

Major Depressive Disorder In The Elderly

Completed· GSK logo

GSK·Phase 3·NCT00093288·364 enrolled

Cocaine Dependence1 trial

Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

Completed·JJohns Hopkins University·Phase 2/3·NCT02111798·83 enrolled

MPA1 trial

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

Not yet recruiting·BBioCorRx Pharmaceuticals Inc·Phase 1·NCT07269873·30 enrolled

Bipolar Disorder1 trial

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Terminated·UUniversity of British Columbia·Phase 3·NCT00958633·237 enrolled

5 more indications

Dysthymic Disorder1 trial

Wellbutrin XL for Dysthymic Disorder

Completed·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00225251·18 enrolled

Memory1 trial

Memory Functioning and Antidepressant Treatment

Completed·UUniversity Health Network, Toronto·Phase 3·NCT00296933·60 enrolled

Major Depression1 trial

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00917059·172 enrolled

Breast Carcinoma1 trial

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer

Completed·NNRG Oncology·Phase 2·NCT03180294·230 enrolled

Unspecified1 trial

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Completed·EEmory University·Phase 4·NCT04352101·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Bupropion XL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupropion XL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupropion XL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Bupropion XL

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

ESS1 trial

Major Depressive Disorder1 trial

Cocaine Dependence1 trial

MPA1 trial

Bipolar Disorder1 trial

Dysthymic Disorder1 trial

Memory1 trial

Major Depression1 trial

Breast Carcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News